Leuprolide Acetate For Depot Suspension is a drug owned by Invagen Pharmaceuticals Inc. It is protected by 1 US drug patent filed in 2018 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Dec 15, 2020. Details of Leuprolide Acetate For Depot Suspension's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US9789064 | Method for delivering a peptide to a subject at a modulated rate via microcapsules of lactic-co-glycolic copolymer containing said peptide |
Dec, 2020
(3 years ago) |
Expired
|
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Leuprolide Acetate For Depot Suspension's patents.
Latest Legal Activities on Leuprolide Acetate For Depot Suspension's Patents
Given below is the list of recent legal activities going on the following patents of Leuprolide Acetate For Depot Suspension.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Expire Patent Critical | 22 Nov, 2021 | US9789064 |
| Maintenance Fee Reminder Mailed Critical | 07 Jun, 2021 | US9789064 |
| Patent Issue Date Used in PTA Calculation Critical | 17 Oct, 2017 | US9789064 |
| Recordation of Patent Grant Mailed Critical | 17 Oct, 2017 | US9789064 |
| Email Notification Critical | 28 Sep, 2017 | US9789064 |
| Issue Notification Mailed Critical | 27 Sep, 2017 | US9789064 |
| Dispatch to FDC | 13 Sep, 2017 | US9789064 |
| Application Is Considered Ready for Issue Critical | 13 Sep, 2017 | US9789064 |
| Issue Fee Payment Verified Critical | 12 Sep, 2017 | US9789064 |
| Issue Fee Payment Received Critical | 12 Sep, 2017 | US9789064 |
US patents provide insights into the exclusivity only within the United States, but Leuprolide Acetate For Depot Suspension is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Leuprolide Acetate For Depot Suspension's family patents as well as insights into ongoing legal events on those patents.
Leuprolide Acetate For Depot Suspension's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Leuprolide Acetate For Depot Suspension's generic launch date based on the expiry of its last outstanding patent is estimated to be Dec 15, 2020 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Leuprolide Acetate For Depot Suspension Generic API suppliers:
Leuprolide Acetate is the generic name for the brand Leuprolide Acetate For Depot Suspension. 8 different companies have already filed for the generic of Leuprolide Acetate For Depot Suspension, with Amneal having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Leuprolide Acetate For Depot Suspension's generic
Alternative Brands for Leuprolide Acetate For Depot Suspension
There are several other brand drugs using the same active ingredient (Leuprolide Acetate) as Leuprolide Acetate For Depot Suspension. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | ||
|---|---|---|---|
| Abbvie Endocrine |
| ||
| Abbvie Endocrine Inc |
| ||
| Ortho Mcneil Janssen |
| ||
| Tolmar |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Leuprolide Acetate, Leuprolide Acetate For Depot Suspension's active ingredient. Check the complete list of approved generic manufacturers for Leuprolide Acetate For Depot Suspension
About Leuprolide Acetate For Depot Suspension
Leuprolide Acetate For Depot Suspension is a drug owned by Invagen Pharmaceuticals Inc. Leuprolide Acetate For Depot Suspension uses Leuprolide Acetate as an active ingredient. Leuprolide Acetate For Depot Suspension was launched by Invagen Pharms in 2018.
Approval Date:
Leuprolide Acetate For Depot Suspension was approved by FDA for market use on 28 August, 2018.
Active Ingredient:
Leuprolide Acetate For Depot Suspension uses Leuprolide Acetate as the active ingredient. Check out other Drugs and Companies using Leuprolide Acetate ingredient
Dosage:
Leuprolide Acetate For Depot Suspension is available in for suspension form for intramuscular use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 22.5MG/VIAL | FOR SUSPENSION | Prescription | INTRAMUSCULAR |